NCT02239900 is a Phase 1 clinical trial of Ipilimumab in Liver Cancer, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT02239900?

NCT02239900 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT02239900?

Interventions in NCT02239900: Ipilimumab, Stereotactic Body Radiation Therapy (SBRT).

What condition does NCT02239900 study?

NCT02239900 studies Liver Cancer, Lung Cancer.

Is NCT02239900 still recruiting?

NCT02239900 is currently completed. Last updated 30 November 2020.

Last reviewed 2020-11-30 · How we verify

NCT02239900

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors

Completed Phase 1 Last updated 30 November 2020

What this trial tests

Phase 1 trial testing Ipilimumab in Liver Cancer in 143 participants. Completed in 25 October 2019.

Timeline

26 August 2014

Primary endpoint
25 October 2019

25 October 2019

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	143
Start date	26 August 2014
Primary completion	25 October 2019
Estimated completion	25 October 2019
Sites	1 location across United States

Drugs / interventions tested

Ipilimumab — full drug profile →
Stereotactic Body Radiation Therapy (SBRT) — full drug profile →

Conditions studied

Liver Cancer — all drugs for Liver Cancer →
Lung Cancer — all drugs for Lung Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Liver Cancer or Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to find the highest tolerable dose of ipilimumab and stereotactic body radiation therapy (SBRT). The safety and effectiveness of these treatments given consecutively will also be studied. This is an investigational study. SBRT is FDA approved for the control of metastatic and primary tumors. Ipilimumab is FDA approved and commercially available for the treatment of metastatic melanoma that cannot be removed with surgery. The use of SBRT with ipilimumab is investigational. The study doctor can explain how the study drug is designed to work. Up to 120 participants will be enrolled in this study. All will take part at MD Anderson.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Ferroptosis, necroptosis, and pyroptosis in anticancer immunity.
Tang R, Xu J, Zhang B, Liu J, et al · · 2020 · cited 939× · PMID 32778143 · DOI 10.1186/s13045-020-00946-7
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy.
Gao W, Wang X, Zhou Y, Wang X, et al · · 2022 · cited 801× · PMID 35725836 · DOI 10.1038/s41392-022-01046-3
Lung cancer immunotherapy: progress, pitfalls, and promises.
Lahiri A, Maji A, Potdar PD, Singh N, et al · · 2023 · cited 737× · PMID 36810079 · DOI 10.1186/s12943-023-01740-y
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.
Bible KC, Kebebew E, Brierley J, Brito JP, et al · · 2021 · cited 464× · PMID 33728999 · DOI 10.1089/thy.2020.0944
Abscopal effect of radiotherapy combined with immune checkpoint inhibitors.
Liu Y, Dong Y, Kong L, Shi F, et al · · 2018 · cited 337× · PMID 30115069 · DOI 10.1186/s13045-018-0647-8
The emerging role of epigenetic therapeutics in immuno-oncology.
Topper MJ, Vaz M, Marrone KA, Brahmer JR, et al · · 2020 · cited 331× · PMID 31548600 · DOI 10.1038/s41571-019-0266-5
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
Bernstein MB, Krishnan S, Hodge JW, Chang JY. · · 2016 · cited 325× · PMID 26951040 · DOI 10.1038/nrclinonc.2016.30
Immune checkpoint therapy in liver cancer.
Xu F, Jin T, Zhu Y, Dai C. · · 2018 · cited 299× · PMID 29843754 · DOI 10.1186/s13046-018-0777-4

Verify or expand the search:

Other trials of Ipilimumab

Trials testing the same drug.

NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07510334 — VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07293351 — A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Caboz · Phase 1, PHASE2 · recruiting
NCT07128680 — Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Met · Phase 1 · recruiting

Other recruiting trials for Liver Cancer

Currently open trials in the same condition.

NCT07295275 — Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection · recruiting
NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07295340 — Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection · recruiting
NCT07504367 — Large Language Models Assist in Tumor MDT · NA · recruiting
NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02239900 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 30 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02239900.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing